Latka logo

AxonJay vs Harper: Revenue, Funding & Team Size Compared

AxonJay generates $2.3M in revenue; Harper generates $2.3M. AxonJay and Harper are close to the same size by revenue. The table below compares AxonJay and Harper on funding, valuation, customers, team size and headquarters — every figure GetLatka has verified for each company.

AxonJay vs Harper compared on revenue, funding, valuation, customers and team size
CompanyAxonJay logoAxonJayThis companyHarper logoHarper
Revenue$2.3M$2.3M
Funding raised$3MNot disclosed
Team size2121
Founded20212024
HQBrussels, BelgiumSan Francisco, United States

Want the full dataset? GetLatka tracks revenue, funding and team history for thousands of SaaS companies, with charts, growth rates and founder interviews.

AxonJay logo

AxonJay at a glance

AxonJay generates $2.3M in revenue with 21 employees, headquartered in Brussels, Belgium.

Revenue
$2.3M
Funding
$3M
Team size
21
Founded
2021

AxonJay, a multi-award-winning company, has built proprietary deep-tech AI-Agents. Accelerate your business in Real-Time and 24/7 with dedicated AI-Agents,on our Self-Machine Learning Platform™. At AxonJay, we bring over 50 years of AI and…

Harper logo

Harper at a glance

Harper generates $2.3M in revenue with 21 employees, headquartered in San Francisco, United States.

Revenue
$2.3M
Team size
21
Founded
2024

AI-native commercial insurance brokerage

Other AxonJay alternatives

AxonJay competes with more than the companies on this page. Browse the full alternative lists to compare revenue, funding and team size across the category.

AxonJay vs Harper: frequently asked questions

Is AxonJay or Harper bigger?

AxonJay is the bigger company by revenue, at $2.3M against $2.3M for Harper.

How much revenue does AxonJay make?

AxonJay generates $2.3M in annual revenue with a team of 21.

How much revenue does Harper make?

Harper generates $2.3M in annual revenue with a team of 21.

How much funding has AxonJay raised?

AxonJay has raised $3M in total funding since it was founded in 2021.